Avid Bioservices, Inc. announced that the company is maintaining revenue guidance for full fiscal year 2024 of $137 million to $147 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.44 USD | -0.67% | -2.23% | +14.46% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.46% | 472M | |
+1.79% | 94.37B | |
-0.66% | 38.14B | |
-13.57% | 32.56B | |
+76.24% | 28.24B | |
-12.73% | 15.98B | |
-2.15% | 13.82B | |
-13.59% | 11.57B | |
+158.88% | 10.52B | |
-52.04% | 9.89B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024